Related references
Note: Only part of the references are listed.Tissue engineered skeletal muscle model of rheumatoid arthritis using human primary skeletal muscle cells
Catherine E. Oliver et al.
JOURNAL OF TISSUE ENGINEERING AND REGENERATIVE MEDICINE (2022)
Involvement of Type I Interferon Signaling in Muscle Stem Cell Proliferation During Dermatomyositis
Laure Gallay et al.
NEUROLOGY (2022)
Chemotherapeutic drug screening in 3D-Bioengineered human myobundles provides insight into taxane-induced myotoxicities
Maria J. Torres et al.
ISCIENCE (2022)
Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis
Hanna Kim et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
Successful management with Janus kinase inhibitor tofacitinib in refractory juvenile dermatomyositis: a pilot study and literature review
Zhongxun Yu et al.
RHEUMATOLOGY (2021)
Exercise mimetics and JAK inhibition attenuate IFN-gamma-induced wasting in engineered human skeletal muscle
Zhaowei Chen et al.
SCIENCE ADVANCES (2021)
Loss of sarcomeric proteins via upregulation of JAK/STAT signaling underlies interferon-γ-induced contractile deficit in engineered human myocardium
Ren-Zhi Zhan et al.
ACTA BIOMATERIALIA (2021)
JAK-inhibitors for dermatomyositis: A concise literature review
Aliza Paudyal et al.
DERMATOLOGIC THERAPY (2021)
JAK inhibitors: a potential treatment for JDM in the context of the role of interferon-driven pathology
Meredyth G. Ll Wilkinson et al.
PEDIATRIC RHEUMATOLOGY (2021)
JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis: a monocentric retrospective study
Tom Le Voyer et al.
RHEUMATOLOGY (2021)
Updates on interferon in juvenile dermatomyositis: pathogenesis and therapy
Hanna Kim
CURRENT OPINION IN RHEUMATOLOGY (2021)
Juvenile dermatomyositis: advances in clinical presentation, myositis-specific antibodies and treatment
Jian-Qiang Wu et al.
WORLD JOURNAL OF PEDIATRICS (2020)
Electrical stimulation increases hypertrophy and metabolic flux in tissue-engineered human skeletal muscle
Alastair Khodabukus et al.
BIOMATERIALS (2019)
Animal Models of Inflammation for Screening of Anti-inflammatory Drugs: Implications for the Discovery and Development of Phytopharmaceuticals
Kalpesh R. Patil et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Muscle Expression of Type I and Type II Interferons Is Increased in Juvenile Dermatomyositis and Related to Clinical and Histologic Features
Gian Marco Moneta et al.
ARTHRITIS & RHEUMATOLOGY (2019)
Myogenic Progenitor Cells Exhibit Type I Interferon-Driven Proangiogenic Properties and Molecular Signature During Juvenile Dermatomyositis
Cyril Gitiaux et al.
ARTHRITIS & RHEUMATOLOGY (2018)
JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis
Leandro Ladislau et al.
BRAIN (2018)
Advances in Juvenile Dermatomyositis: Myositis Specific Antibodies Aid in Understanding Disease Heterogeneity
Lauren M. Pachman et al.
JOURNAL OF PEDIATRICS (2018)
Type I Interferons: Distinct Biological Activities and Current Applications for Viral Infection
Shi-fang Li et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2018)
Race, Income, and Disease Outcomes in Juvenile Dermatomyositis
Kathryn Phillippi et al.
JOURNAL OF PEDIATRICS (2017)
Human, Tissue-Engineered, Skeletal Muscle Myobundles to Measure Oxygen Uptake and Assess Mitochondrial Toxicity
Brittany N. J. Davis et al.
TISSUE ENGINEERING PART C-METHODS (2017)
IFN-β-induced reactive oxygen species and mitochondrial damage contribute to muscle impairment and inflammation maintenance in dermatomyositis
Alain Meyer et al.
ACTA NEUROPATHOLOGICA (2017)
Tissue engineering Approaches in the Design of Healthy and Pathological In Vitro Tissue Models
Silvia Caddeo et al.
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY (2017)
Alpha and Beta Type 1 Interferon Signaling: Passage for Diverse Biologic Outcomes
Cherie T. Ng et al.
CELL (2016)
The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes
L. G. Rider et al.
JOURNAL OF INTERNAL MEDICINE (2016)
The role of type I interferons and other cytokines in dermatomyositis
Ashish Arshanapalli et al.
CYTOKINE (2015)
Bioengineered Human Myobundles Mimic Clinical Responses of Skeletal Muscle to Drugs
Lauran Madden et al.
ELIFE (2015)
Is animal research sufficiently evidence based to be a cornerstone of biomedical research?
Pandora Pound et al.
BMJ-BRITISH MEDICAL JOURNAL (2014)
Type 1 Interferons Inhibit Myotube Formation Independently of Upregulation of Interferon-Stimulated Gene 15
Sara Franzi et al.
PLOS ONE (2013)
Anti-Melanoma Differentiation-Associated Gene 5 Antibody is a Diagnostic and Predictive Marker for Interstitial Lung Diseases Associated with Juvenile Dermatomyositis
Ichiro Kobayashi et al.
JOURNAL OF PEDIATRICS (2011)
Type I interferon and Toll-like receptor expression characterizes inflammatory myopathies
C. Cappelletti et al.
NEUROLOGY (2011)
The type I interferon system in idiopathic inflammatory myopathies
Ingrid E. Lundberg et al.
AUTOIMMUNITY (2010)
Skeletal muscle: Energy metabolism, fiber types, fatigue and adaptability
Hakan Westerblad et al.
EXPERIMENTAL CELL RESEARCH (2010)
Dermatomyositis and Type 1 Interferons
Steven A. Greenberg
Current Rheumatology Reports (2010)
Elevated Serum Interferon-α Activity in Juvenile Dermatomyositis Associations With Disease Activity at Diagnosis and After Thirty-Six Months of Therapy
Timothy B. Niewold et al.
ARTHRITIS AND RHEUMATISM (2009)
Animal models in myositis
Yasuhiro Katsumata et al.
CURRENT OPINION IN RHEUMATOLOGY (2008)
Signs of inflammation in both symptomatic and asymptomatic muscles from patients with polymyositis and dermatomyositis
C. Dorph et al.
ANNALS OF THE RHEUMATIC DISEASES (2006)
Role of major histocompatibility complex class I molecules in autoimmune myositis
K Nagaraju
CURRENT OPINION IN RHEUMATOLOGY (2005)
Activation of the endoplasmic reticulum stress response in autoimmune myositis - Potential role in muscle fiber damage and dysfunction
K Nagaraju et al.
ARTHRITIS AND RHEUMATISM (2005)
US incidence of juvenile dermatomyositis, 1995-1998: Results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry
EP Mendez et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2003)
Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodies
K Nagaraju et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Share Paper
